drugset
drugset / Trial / NCT02231489

Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

NCT02231489 ↗

Phase 1 Completed 12 enrolled Janssen Research & Development, LLC
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the relative bioavailability of JNJ-42756493 oral dose of capsule (reference) versus tablet (test) in healthy participants.

Timeline

Start
2014-09
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Erdafitinib Small molecule 10 mg Oral
Background JNJ-61818549 Unknown 100 ug Intravenous

Indications

No indication recorded.